SCHEMBL5786281

SCHEMBL5786281

Fc1ccc(-c2nc(N3CCNCC3)nc3cc(F)ccc23)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
HTR2A P28223 2/20 0.45
KDM4E B2RXH2 2/20 0.44
S1PR2 O95136 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
HIF1A Q16665 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PRKCB P05771 3/20 0.43
PRKCA P17252 3/20 0.43
PRKCH P24723 3/20 0.43
PRKCE Q02156 3/20 0.43
PRKCQ Q04759 3/20 0.43
PRKCD Q05655 3/20 0.43
CASP1 P29466 1/20 0.41
CASP4 P49662 1/20 0.41
CASP5 P51878 1/20 0.41
DPP4 P27487 1/20 0.41
APAF1 O14727 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787788 0.91 KDM4E (0.46) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5787458 0.90 ALDH1A1 (0.53) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5785662 0.90 ALDH1A1 (0.63) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5787210 0.90 KDM4E (0.52) ALDH1A1HPGDHTR2AKDM4ES1PR2
Hydrochloric Acid SCHEMBL5789034 0.89 ALDH1A1 (0.62) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5787147 0.88 KDM4E (0.47) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5788559 0.88 ALDH1A1 (0.47) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5787181 0.86 ALDH1A1 (0.48) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5788424 0.85 ALDH1A1 (0.47) ALDH1A1HPGDHTR2AKDM4ES1PR2
SCHEMBL5787010 0.85 ALDH1A1 (0.52) ALDH1A1HPGDHTR2AKDM4ES1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685115-A1 NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Warner-Lambert Company LLC (US) 2006-08-02 EP claimed
WO-2005042501-A1 NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WARNER-LAMBERT COMPANY LLC (US) 2005-05-12 WO claimed
US-20050096327-A1 Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders WARNER-LAMBERT COMPANY LLC 2005-05-05 US claimed
EP-1685115-A1 NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Warner-Lambert Company LLC (US) 2006-08-02 EP disclosed
WO-2005042501-A1 NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WARNER-LAMBERT COMPANY LLC (US) 2005-05-12 WO disclosed
US-20050096327-A1 Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders WARNER-LAMBERT COMPANY LLC 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096327-A1 Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders SLC6A2, SLC18A2, SLC6A3 ALDH1A1 730/4885HPGD 2714/4885HTR2A 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.